Talk:Biocompatibles
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||
|
External links modified
[edit]Hello fellow Wikipedians,
I have just modified one external link on Biocompatibles. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
- Added archive https://web.archive.org/web/20080517094206/http://www.biocompatibles.com/docLib/46a4d0583ffda08c1175758aef15eed3 to http://www.biocompatibles.com/docLib/46a4d0583ffda08c1175758aef15eed3
When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}}
(last update: 5 June 2024).
- If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
- If you found an error with any archives or the URLs themselves, you can fix them with this tool.
Cheers.—InternetArchiveBot (Report bug) 17:55, 20 July 2017 (UTC)
Cellmed
[edit]This article is about Biocompatibles. I suggest that information presented about Cellmed is not relevant to this article and should be removed. I propose removing the following sentences as they do not advance, nor seem relevant to this article:
Cellmed in Alzenau, Germany, is developing a drug-eluting bead product for the treatment of stroke, based on proprietary stem cell technology. Cellmed is also developing a [GLP-1] analogue for the treatment of [diabetes] and [obesity] partnered with [AstraZeneca].
Please respond with thoughts - agree or disagree? Thank you. Curdigirl (talk) 19:42, 21 October 2019 (UTC)